The Vaxine team based at Flinders in Adelaide led by Nikolai Petrovsky has for the last 20 years been developing novel vaccines and drugs against pathogens that pose major public health or biodefense threats including influenza, Ebola, HIV, malaria, tuberculosis, anthrax, ricin and COVID-19 with funding support from the US National Institutes of Health. The team has employed the latest technologies in synthetic gene design, biofermentation, computer-aided design and artificial intelligence to help accelerate vaccine development. This talk will discuss the general landscape of biodefense vaccine development worldwide, including progress of Vaxine’s Covax-19 candidate which remains the only active Australian clinical-stage COVID-19 vaccine candidate.
0:00 Webinar welcome
1:09 Introducing Professor Nikolai Petrovsky
2:03 Prof Petrovsky on COVID-19 vaccine challenges
50:50 Q&A
--
Professor Nikolai Petrovsky
Research Director, Vaxine Pty Ltd and Professor of Medicine, Flinders University
Nikolai Petrovsky is Chairman and Research director of Vaxine Pty Ltd, an Adelaide-based biotechnology company focused on vaccine development, together with being a Professor of Medicine at Flinders University and Director of Endocrinology at Flinders Medical Centre. Over the last 16 years he has been principal investigator on five NIH vaccine grants totaling over 50 million dollars, with a focus on development of vaccine adjuvants and pandemic vaccine platforms. He has authored over 200 research papers and has won prestigious awards including 2010 Ernst & Young Entrepreneur of the Year Award. His current focus is development of the Covax-19 vaccine against COVID-19.
https://kirby.unsw.edu.au/event/professor-nikolai-petrovsky-vaccines-and-biodefense-covid-19-flu-and-beyond
Opinions expressed in the Kirby Institute Seminar Series are solely those of the speaker and do not necessarily represent the views or opinions of the Kirby Institute or UNSW. 
0 Comments